Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin and Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age greater than or equal to 60 Years)

Next Previous
Trial Profile

Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin and Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age greater than or equal to 60 Years)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clofarabine (Primary) ; Cytarabine; Daunorubicin; Fludarabine
  • Indications Acute myeloid leukaemia; Graft-versus-host disease
  • Focus Therapeutic Use
  • Acronyms ECOG-ACRIN E2906

    • Most Recent Events

    • 12 Dec 2023 Results of prospective patient-reported outcomes (PRO) assessment of HRQoL and fatigue to understand treatment impact from the patients(pts) perspective, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 14 Dec 2021 Results of post remission data from the prospective ECOG-ACRIN E2906 study assessing all patients who received alloSCT either on protocol during first remission (CR1) or at other post induction time-points, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
    • 23 Feb 2021 Planned primary completion date changed from 15 Jan 2021 to 15 Mar 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top